LINC00106: A Non-Protein Coding RNA Regulator of Gene Expression and Cell Development

Target Name: LINC00106

NCBI ID: G751580

LINC00106

Other Name(s): Long intergenic non-protein coding RNA 106 | long intergenic non-protein coding RNA 106 | CXYorf8 | NCRNA00106

LINC00106: A Non-Protein Coding RNA Regulator of Gene Expression and Cell Development

LINC00106 is a non-protein coding RNA (ncRNA) molecule that has been identified in various studies as having a key role in regulating gene expression and cell development. LINC00106 is a long intergenic non-protein coding RNA which means it is not a protein but it can interact with proteins and other RNAs to regulate gene expression.

The LINC00106 gene is located on chromosome 6p21 and it encodes a protein of approximately 210 amino acids. However, recent studies have shown that the full-length RNA transcript of LINC00106 is longer than the protein transcript, and it is not clear if the protein produced by the LINC00106 gene is a full-length transcript.

LINC00106 is a key regulator of gene expression and has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that LINC00106 is downregulated in various types of cancer, and that increasing its expression levels can inhibit the growth of cancer cells.

In addition, LINC00106 has also been shown to play a role in the regulation of cell adhesion and migration. LINC00106 has been shown to interact with the protein E-cadherin, which is a cell adhesion molecule that helps to maintain the integrity of tissues and organs.

LINC00106 has also been shown to play a role in the regulation of stem cell proliferation and self-renewal. LINC00106 has been shown to interact with the protein Nanog, which is a regulator of stem cell proliferation and self-renewal.

LINC00106 has also been shown to play a role in the regulation of tissue repair and regeneration. LINC00106 has been shown to interact with the protein Fas, which is a protein that plays a role in the regulation of cell death and tissue repair.

In addition, LINC00106 has also been shown to play a role in the regulation of the immune response. LINC00106 has been shown to interact with the protein PDGF-RG, which is a protein that plays a role in the regulation of cell growth and differentiation, including the immune response.

LINC00106 has also been shown to play a role in the regulation of cell signaling pathways. LINC00106 has been shown to interact with the protein p180, which is a protein that plays a role in cell signaling pathways, including the regulation of cell growth and differentiation.

In conclusion, LINC00106 is a non-protein coding RNA molecule that has been shown to play a key role in regulating gene expression and cell development. LINC00106 is a long intergenic non-protein coding RNA which means it is not a protein but it can interact with proteins and other RNAs to regulate gene expression. LINC00106 has been shown to play a role in the regulation of various diseases including cancer, cell adhesion and migration, stem cell proliferation and self-renewal, tissue repair and regeneration and immune response. Therefore, LINC00106 may be a potential drug target or biomarker for various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 106

The "LINC00106 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00106 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets